Modalis Therapeutics program for LAMA2-RD gene therapy granted Rare Pediatric Disease Designation by FDA.

Long-awaited publication about the Phase 1 Open-Label Study of Omigapil in Patients With LAMA2- or COL6-Related Dystrophy now published.

Please see the end of this article for Frequently Asked Questions - CALLISTO Phase 1 Clinical Trial Pratteln, Switzerland, April 5, 2018...